US07725L1026 - ADR
BeiGene's biologics license application for Tevimbra, a combination therapy for gastric cancer, has been accepted by the FDA, with a target action date set...
BeiGene receives positive CHMP opinion for tislelizumab, an anti-PD-1 treatment for non-small cell lung cancer, expanding its potential indications.
BeiGene reported fourth-quarter and full-year 2023 financial results, with a GAAP EPS of -$3.53, beating estimates by $0.38.
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.
/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...
These five biotech companies could have a lot of room to run.
The U.S. FDA grants orphan drug designation to BeiGene's sonrotoclax for relapsed/refractory multiple myeloma treatment.
BeiGene (BGNE) agrees to pay over $1B for exclusive global rights to a cancer candidate developed by Ensem Therapeutics. Read more here.
BeiGene's drug, Brukinsa, has received EU approval for the treatment of follicular lymphoma, expanding its indication range in the region.